Natera, Inc. (NTRA)
NTRA moved a median of +0.18% 30 minutes after news, and +0.37% by the close. How NTRA actually reacts to news — the realized, point-in-time move the market made, measured across 956 labeled events over the last three years with zero look-ahead.
NTRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.08% | 55% | 955 |
| 30-min | +0.18% | 56% | 955 |
| 60-min | +0.27% | 58% | 955 |
| to close | +0.37% | 57% | 949 |
| Middle 50% of NTRA reactions | -0.69% to +1.21% |
|---|---|
| Median reaction (30-min) | +0.18% |
| Measured reactions | 956 |
Half of all Natera, Inc. news events land between -0.69% and +1.21% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NTRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 27 | -0.17% | 44% | +0.92% |
| Analyst downgrades | 15 | +0.25% | 67% | -0.40% |
| Coverage initiations | 35 | -0.55% | 37% | -0.09% |
| Rating reiterations | 139 | +0.03% | 51% | +0.37% |
| Price-target raises | 66 | +0.03% | 53% | +0.56% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how NTRA ranks against every other measured name →
That’s how NTRA usually reacts — get an email when it moves on news →Email me when NTRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NTRA's baseline. Nothing else.
Recent NTRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma | Press release | Business Wire | +0.35% | -0.07% | |
| Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer | Press release | Business Wire | -0.00% | -1.50% | |
| Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ | Press release | Business Wire | +0.19% | +0.37% | |
| Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers | Press release | Business Wire | +0.57% | +0.79% | |
| Form 10-Q Natera, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.38% | +0.37% | |
| Form S-8 Natera, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.77% | — | |
| Form 8-K Natera, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | +0.37% | |
| Natera Reports Second Quarter 2026 Financial Results | Press release | Business Wire | -2.38% | +0.37% | |
| Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer | Press release | Business Wire | +0.52% | -0.21% | |
| Natera to Report its Second Quarter Results on August 6, 2026 | Press release | Business Wire | +1.41% | +6.84% | |
| Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study | Press release | Business Wire | +0.89% | +0.21% | |
| Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio | Press release | Business Wire | +0.65% | +2.26% | |
| Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers | Press release | Business Wire | +1.07% | +2.14% | |
| Form 8-K Natera, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -1.14% | |
| Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer | Press release | Business Wire | -0.02% | +2.27% | |
| Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer | Press release | Business Wire | +0.97% | +2.76% | |
| Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial | Press release | Business Wire | +2.99% | +0.70% | |
| Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer | Press release | Business Wire | +1.72% | +7.43% | |
| NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update | Press release | Business Wire | +1.89% | +4.01% | |
| Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress | Press release | Business Wire | +1.00% | -0.47% | |
| Form 8-K Natera, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +3.31% | |
| Form 8-K/A Natera, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +3.31% | |
| Form 8-K Natera, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -1.11% | |
| Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer | Press release | Business Wire | -0.28% | +3.81% | |
| Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors | Press release | Business Wire | -2.51% | +0.92% | |
| Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma | Press release | Business Wire | +0.79% | +3.91% | |
| Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer | Press release | Business Wire | -0.24% | +5.57% | |
| Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology | Press release | Business Wire | -1.33% | -2.22% | |
| Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World | Press release | Business Wire | -1.85% | -0.52% | |
| Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology | Press release | Business Wire | +1.57% | -0.58% | |
| EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled | Press release | Business Wire | -0.87% | +2.59% | |
| Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) | Press release | Business Wire | +0.33% | -1.06% | |
| Form 10-Q Natera, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.77% | -7.50% | |
| Form 8-K Natera, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -7.50% | |
| Natera Reports First Quarter 2026 Financial Results | Press release | Business Wire | +0.77% | -7.50% | |
| Natera to Report its First Quarter Results on May 7, 2026 | Press release | Business Wire | +1.40% | +4.79% | |
| Form ARS Natera, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.18% | +1.30% | |
| Form DEF 14A Natera, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -0.18% | +1.30% | |
| Form DEFA14A Natera, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.18% | +1.30% | |
| Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT | Press release | Business Wire | +0.05% | +0.18% | |
| Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma | Press release | Business Wire | +1.40% | +4.22% | |
| Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents | Press release | Business Wire | -0.41% | -3.03% | |
| 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform | Press release | Business Wire | -0.18% | +1.94% | |
| Form 8-K Natera, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | +4.94% | |
| SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery | Press release | Business Wire | +0.38% | +5.07% | |
| Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers | Press release | Business Wire | +1.44% | +3.26% | |
| MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 | Press release | PR Newswire | -0.15% | -1.77% | |
| Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis | Press release | Business Wire | -0.15% | -1.77% | |
| Form S-8 Natera, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.14% | +0.00% | |
| Form 10-K Natera, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.06% | -1.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NTRA section they belong to.
Where else NTRA is measured.
NTRA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Athenex, Inc. (ATNX) | 964 | -0.43% | 41% |
| Sage Therapeutics, Inc. (SAGE) | 957 | -0.14% | 41% |
| Geron Corporation (GERN) | 952 | -0.28% | 41% |
| Antares Pharma, Inc. (ATRS) | 951 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Natera, Inc.'s median reaction calculated?
Every labeled NTRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 956 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of NTRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does NTRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.